Eli Lilly's Alzheimer's candidate delayed — again
Eli Lilly’s Alzheimer’s disease drug, donanemab, faces further delays as US regulators plan to hold a hearing with outside advisors to examine how safe the treatment is and how well it works.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly ramps up in the Nordics ahead of major launches
For subscribers